An in vitro study has identified potent antibiotic properties possessed by cannabidiol, discovering activity against Gram-positive bacteria such as Staphylococcus aureus and Streptococcus pneumoniae.
Browsing: Drug Development
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.
ECCMID19: Suvratoxumab completes Phase II for treatment of Staphylococcus aureus in the New Drugs 4 Bad Bugs program
Collaborative research efforts have seen a novel monoclonal antibody, suvratoxumab, complete a Phase II trial targeted towards Staphylococcus aureus. This SAATELLITE study comes as the first clinical trial in the Innovative Medicines Initiative, formed to develop alternative medicines to combat antibiotic resistance.
A single, oral dose of antimalarial DSM265 has cleared seven volunteers of a Plasmodium falciparum infection, according to the trial from the Medicines for Malaria Venture.
Take a look behind the scenes of a recent Future Virology review, entitled: ‘TRIM proteins: an emerging antiviral protein family’, as we ask the authors about TRIM proteins, viral resistance and the future of this field.
Take a look at this month’s industry headlines including Priority Review for two antibacterial agents from Merck (NJ, USA), a clinical trial for a new malaria drug and the launch of omadacycline in the USA.
Take a look behind the scenes of a recent Future Microbiology review as we ask the authors about quorum quenching and using nanoparticles as antibiotics.
New research has developed a nanoparticle formulation that can knock down a key chlamydia binding protein and simultaneously induce autophagy – showing promise against this infection.
Some of the challenges with mass ivermectin administration could be addressed with new drugs or drug combinations with higher effect for the parasite – leading us to ask, what new treatments are currently in the clinical pipeline?
The UK government has published a 20-year vision and a 5-year national action plan for how the UK will contribute to controlling and containing antimicrobial resistance by 2040.